Our team includes first-in-class experts in oncology, neurology, clinical development, and regulatory affairs from around the world. We are working to advance new approaches to treat illness with nuclear medicine.
We address illnesses for underserved patients. Several of our development initiatives focus on rare pediatric disease. We also target hard-to-cure conditions such as Parkinson's Disease and Breast Cancer by leveraging our expertise to advance clinical management of these diseases.
Patient-Centricity: Where our work begins and ends
Biotechnology and pharmaceutical innovation expands at a rapid moving pace. We start by communicating with patients and clinicians to understand their stories. Our advocacy for those underserved by innovation fuels the aims of our efforts.
Bio-Technology: Making distinctive solutions unique peoples
Radiopharmaceutical innovation and development are the pillars of our efforts. We advance cutting-edge biotechnology using a lean process and synergistic connectivity with our expert advisors. This fuels us to make first-in-class solutions for challenging problems in healthcare, including:
Rare Pediatric Disease
Partnerships: Global connections making a global impact
Our partners recognize the need to help patients who are underserved by medical innovation. Serving these patients requires support from around the world - university researchers, nuclear physicians, radiologists, clinical specialists, foundations, and government partnerships, collectively advancing innovation and contributing their resources to our mission. With our collective efforts, we are combining the best resources to develop solutions rapidly for patients and the clinicians who manage their care.
Culture: Advancing innovation by inclusion and diversity
Our team and collaborators are diverse people working together to foster a culture of inclusion. This is because the best ideas and decisions are made when they're reflected by our divergent personal and professional experiences. With this diversity, members of the AIP team share one convergent viewpoint, that the results we make in healthcare is more than professional success, the results are personal because we're improving the lives of many underserved patients from around the world.
AIP is a young company with contemporary values. These values serve as markers along the pathway of drug discovery, helping us empathize with patients' viewpoints first, to designing strategy, and even in clinical protocol development to serve these patients and their clinicians well. These markers keep us on target every day as we're making leaps and bounds in our drug development efforts.
Stanley Satz, Chief Science Officer and Chairman
AIP was founded in 2017 by father-and-daughter team Stanley and Roseanne Satz. AIP is a new kind of biotechnology and pharmaceutical company - one with a contemporary culture yet powered by first-in-class experts in nuclear physics and medicine, medical imaging, and regulatory affairs from around the world.
Our name reflects our company's desire to bring rapid transformation by combining therapeutic and diagnostic practice, elevating early detection, and clinical management of diseases.
Today & Tomorrow
Today we're entering into several clinical trials for rare pediatric disease imaging diagnostics.
Tomorrow we plan to raise the quality of life for those families, as they seek answers towards diagnosis, as they seek clinical evaluation of their child's therapy.
Today we are developing products to assist in the active clinical management of oncological and neurological diseases.
Tomorrow we plan to provide predictive and personalized technology that will enhance these patients' care.